抗ウィルス剤の市場分析：市場を形成する疾病と薬剤の概要

Introduction

While each viral indication, ranging from HIV to influenza, presents unique challenges, there are a number of issues that companies developing and marketing drugs across this field face. Curative therapies are rare, drug resistance is becoming increasingly problematic and the introduction of novel vaccines threatens the market for many antivirals.

Scope of this Report

• Detailed analysis of the global antiviral market, focusing on HIV, hepatitis, herpes and influenza
• Assessment of each viral indication, characterized by 2002 market value, forecasted growth and current clinical unmet need
• Insight into antiviral research and development activity
• Discussion of the various options for more effective life cycle and portfolio management strategy

Report Highlights

• The antiviral market is set to demonstrate positive growth up until 2011, driven predominantly by the increased availability of hepatitis B treatments.
• Growing disease awareness, particularly of recently characterized infections, such as HCV, will continue to drive patient potential by increasing presentation rates.
• Broad-spectrum antivirals present companies with good opportunities to implement life-cycle management initiatives.

Key Reasons to buy this Report

• Determine the characteristics that define antiviral markets and their relative potential
• Understand the key drivers and resistors of antiviral market growth
• Identify life-cycle management options that help to optimize and extend product revenue

TABLE OF CONTENTS

• Introduction 6
• Scope and coverage of the Brief 6
• Key findings about the antiviral market 7

CHAPTER 1 MARKET OVERVIEW 11

• The global antiviral market 11
• Key players 14

CHAPTER 2 DISEASE FOCUS 15

• Introduction 15
• HIV 15
• Disease overview 15
• Patient potential 16
• Market dynamics 18
• Current treatments 18
• Current market value and future focus 19
• Herpes 22
• HSV-1 and HSV-2 22
• Patient potential 23
• CMV 23
• Patient potential 24
• Market dynamics 25
• Hepatitis C 26
• Disease overview 26
• Patient potential 27
• Market dynamics 29
• Current treatment 29
• Future focus 30
• Hepatitis B 31
• Disease overview 31
• Patient potential 32
• Market dynamics 33
• Influenza 34
• Disease overview 34
• Patient potential 35
• Market dynamics 37
• RSV 38
• Disease overview 38
• Patient potential 38
• Market dynamics 39
• Summary 40
• Common drivers of antiviral market growth 40
• Common limits to market growth 41

CHAPTER 3 FUTURE FOCUS 43

• Research and development 43
• Life-cycle and portfolio management 44
• Case study: lamivudine life-cycle management 45
• Portfolio design 45

APPENDIX 47

• Bibliography 47
• Websites 50
• Market attractiveness matrix methodology 52
• Disclaimer 55